Alumis files corporate deck outlining precision TYK2 inhibitors
Alumis Inc. submitted an exhibit detailing its precision engineered TYK2 inhibitors and pipeline strategy. The presentation provides an overview of clinical plans regarding envudeucitinib and future therapies for immune-mediated diseases.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day